Bial-portela Ca & S.a.

Portela, C.a., S.a.

Other

Stemmatters, Biotecnologia E Medicina Regenerativa, S.a.

Stemmatters, Biotecnologia E Medicina Regenerativa

Bial-portela & Cª, S.a.

David Alexander Learmonth

Alexander Beliaev

Laszlo Erno Kiss

Pedro Nuno Leal Palma

Humberto Dos Santos Ferreira

Patricio Manuel Vieira Araujo Soares Da Silva

Jorge Bruno Reis Wahnon

Antonio Zanotti-Gerosa

Gabriela Alexandra Grasa

Patricio Manuel Soares Da Silva

Patrício Manuel Vieira Araújo Soares Da Silva

Tibor Eszenyi

Patricio Manuel V A Soares Da Silva

Patricio Manuel Araujo Soares Da Silva

Michael Kreis

Jean-Marie Schneider

Klaus Reiter

William Maton

Domenico Russo

Jonathan Madec

Patricio Manuel Viera Araújo Soares Da Silva

Jan Benes

Wenge Li

Rui Pedro Romero Amandi De Sousa

Teresa Lucia Silva Pereira Nunes

Matthias Kraemer

Lyndon Christopher Wright

Brian Broadbelt

Cristina Correia

Bjoern Schlummer

Axel Zimmermann

Patricio Manuel Viera Araujo Soares Da Silva

Carla Patrícia Da Costa Pereira Rosa

Patrício Manuel Vieira Araujo Soares Da Silva

Guenter Weingaertner

Patricia Andres

Ekaterina Albert

Keith Lorimer

Bing Yu

Rui Luis Gonçalves Dos Reis

Kevin Wayne Meyer

Patricio Manuel Vieira Araújo Soares Da Silva

Rita Gusmao De Noronha

Patricio Mva Soares Da Silva

Günter Weingaertner

Álmosné Kovách

Rita Gusmãmo De Noronha

Günter Weingärtner

Patrício Manuel Vieira ARAÚJO Soares Da Silva

Jose Luis De Almeida

Klaus Rieter

Patricio Manuel Da Silva

Almosne Kovach

Pedro Nuno Palma

Axel Zimmerman

Carla Patricia Rosa

Administration regime for nitrocatechols

Gellan gum-based hydrogels are disclosed herein for in vitro cell culture and tissue engineering and regenerative medicine applications. Such gellan gum-based hydrogels may be used alone or combined with live cells and/or biomolecules for application in humans and/or animals. Chemical modification of gellan gum with selected ion-chelating substituents affords novel gellan gum hydrogels endowed with tunable physicochemical and biological properties. The modified gellan gum hydrogels described herein present advantages over existing hydrogel systems, including solubility, ionic crosslinking versatility, ease of formulation and injectability and greater adhesiveness within biological tissues and surfaces, whilst maintaining encapsulated cells viable during long culture periods and up-regulating the expression of healthy extracellular matrix markers.

Gellan gum hydrogels, preparation, methods and uses thereof

The present disclosure relates to gellan gum and gellan gum-based hydrogels (GG-based hydrogels) for promoting chondrogenic, osteogenic and adipogenic differentiation of human mesenchymal stem cells, preferentially osteogenic. The present disclosure also relates to a composition for use in bone, cartilage and soft tissue engineering and regenerative medicine, preferably for use in bone.

Gellan gum-based hydrogels, methods and uses thereof

New compounds of formula I are described. The compounds have potentially valuable pharmaceutical properties in the treatment of some central and peripheral nervous system disorders.

Nitrocatechol derivatives as COMT inhibitors

A compound of formula (I) where R, R, X, Y, n, m, R, R, R, Rand Rare as defined herein, for use in the prophylaxis or treatment of a central and peripheral nervous system disorder, wherein the compound of formula (I) is administered prior to sleep, before bedtime or at bedtime.

The present invention relates to a process for preparing (R)-5-(2-(benzylamino)ethyl)-1-(6,8-difluorochroman-3-yl)-1H-imidazole-2(3H)-thione, and pharmaceutically acceptable salts thereof, especially the hydrochloride salt. The invention also relates to a process for making intermediates useful in the formation of said compound, and to the intermediates, per se.

Process for preparing 1,3-dihydroimidazole-2-thione derivatives

This invention relates to novel polymorphs of (HO)NO(CH)&#x2014;(CNO)&#x2014;(CN)(CH)ClO, to processes for their preparation, and to pharmaceutical compositions containing said novel polymorphs as active pharmaceutical ingredient.

Crystal forms of 5-[3-(2,5-dichloro-4, 6-dimethyl-1-oxy-pyridine-3-yl)[1,2,4]oxadiazol-5-yl]-3-nitrobenzene-1,2-diol

The invention relates to the use of an oxodiazolyl compound (I) for the preparation of a medicament for the prevention or treatment of central and peripheral nervous system associated disorders, wherein said medicament is administered according to a dosing regimen having a dosing periodicity ranging from about twice a day to about once every other day.

Dosage regimen for COMT inhibitors

A process for preparing (S)-(+)-10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5-carboxamide or (R)-(&#x2212;)-10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5-carboxamide, by reduction of oxcarbazepine in the presence of a catalyst and a hydride source is disclosed. The catalyst is prepared from a combination of [RuX(L)]wherein X is chlorine, bromine or iodine, and L is an aryl or aryl-aliphatic ligand, with a ligand of formula (A) or formula (B): wherein Ris chosen from Calkoxy and Calkyl, n is a number from 0 to 5, and when n is a number from 2 to 5, Rcan be the same or different, and Ris alkyl, substituted alkyl, aryl, substituted aryl, alkaryl or substituted alkaryl. The hydride source is either NRRRand formic acid, [RRRNH][OOCH] and optionally formic acid, or [M][OOCH]and formic acid, wherein R, Rand Rare Calkyl, M is an alkali metal or alkaline earth metal and x is 1 or 2. A pH from 6.5 to 8 is maintained during the process.

Asymmetric catalytic reduction of oxcarbazepine

Compounds of formula I and a method for their preparation are described: where R, Rand Rare the same or different and signify hydrogens, halogens, alkyl, nitro, amino, alkylcarbonylamino, alkylamino or dialkylamino group; Rsignifies -alkyl-aryl or -alkyl-heteroaryl; X signifies CH, oxygen atom or sulphur atom; n is 2 or 3; including the individual (R)- and (S)-enantiomers or mixtures of enantiomers thereof; and including pharmaceutically acceptable salts and esters thereof. The compounds have potentially valuable pharmaceutical properties for the treatment of cardiovascular disorders such as hypertension and chronic heart failure.

1,3-dihydroimidazole-2-thione derivatives as inhibitors of dopamine-beta-hydroxylase

There is disclosed a methylated intermediate which may be demethylated to provide an inhibitor of catechol-O-methyltransferase useful in the treatment of Parkinson's disease. Also disclosed are methods of making and using said intermediate.

Chemical compound useful as intermediate for preparing a catechol-O-methyltransferase inhibitor

A process for preparing a substitute urea of Formula (II) or Formula (I), or a pharmaceutically acceptable salt or ester thereof: the process comprising the reaction of a carbamate of Formula (II'): Formula (I&#x2032;): with a primary or secondary amine of the formula R1R2NH, wherein ring A, and R1, R2, R5, V, W, X, Y and Z are as defined herein.

Process for the synthesis of substituted urea compounds

This invention relates to novel substituted nitrocatechol derivatives, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them.

Pharmaceutical compounds

The invention relates to compounds and compositions for inhibiting the enzyme fatty acid amide hydrolase (FAAH), the use of the compounds in therapy and, in particular, for treating or preventing conditions whose development or symptoms are linked to substrates of the FAAH enzyme, and methods of treatment or prevention using the compounds and compositions.

Growing community of inventors

Alfena, Portugal

David Alexander Learmonth